Overview

A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

Status:
Active, not recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sun Yat-sen University